

# Atara Biotherapeutics to Participate at Two Upcoming Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that members of the Company's management team will participate at two upcoming conferences in September:

## **CAR-TCR Summit 2018**

- Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate in a session titled "Next Generation CAR-TCR Therapies: Executive Leaders' Fireside Chat" on Thursday, September 6, 2018 at 9:30 a.m. EDT.
- Dietmar Berger, M.D., Ph.D., the Company's Global Head of Research and Development, will give a presentation on Wednesday, September 5, 2018 at 11:15 a.m. EDT. He will then participate in a panel discussion on Thursday, September 6, 2018 at 5:15 p.m. EDT. The conference will be held at the Seaport Hotel & World Trade Center in Boston, MA.

## **Morgan Stanley 16th Annual Global Healthcare Conference**

- Dr. Ciechanover will participate in a fireside chat on Wednesday, September 12, 2018 at 2:15 p.m. EDT. The conference will be held at the Grand Hyatt Hotel in New York, NY.

A live audio webcast of the fireside chat discussion at the Morgan Stanley Global Healthcare Conference will be available by visiting the Investors section of the Atara website. An archived replay of the webcast will be available on the Company's website for 14 days following the live fireside chat discussion.

## **About Atara Biotherapeutics, Inc.**

[Atara Biotherapeutics, Inc. \(@Atarabio\)](#) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara's most advanced T-cell immunotherapy in development, tab-cel™ (tabelecleucel), is being developed for the treatment of patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTL), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing off-the-shelf, allogeneic ATA188 and autologous ATA190 T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Atara's clinical pipeline also includes ATA520 targeting Wilms Tumor 1, or WT1, and ATA230 directed against cytomegalovirus, or CMV. The company was founded in 2012 and is headquartered in South San Francisco, California.

## **INVESTOR & MEDIA CONTACTS:**

### **Investors:**

John Craighead, Atara Biotherapeutics  
650-410-3012

[jcraighead@atarabio.com](mailto:jcraighead@atarabio.com)


Steve Klass, Burns McClellan  
212-213-0006 x331

[sklass@burnsmc.com](mailto:sklass@burnsmc.com)

### **Media:**

Nancie Steinberg, Burns McClellan  
212-213-0006 x318

[nsteinberg@burnsmc.com](mailto:nsteinberg@burnsmc.com)



Source: Atara Biotherapeutics, Inc.